Amneal Pharmaceuticals (NASDAQ:AMRX) Sets New 52-Week High – Still a Buy?

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)’s stock price hit a new 52-week high on Tuesday . The company traded as high as $13.56 and last traded at $13.5250, with a volume of 247363 shares traded. The stock had previously closed at $13.41.

Analyst Upgrades and Downgrades

AMRX has been the subject of several research reports. Truist Financial set a $15.00 price target on shares of Amneal Pharmaceuticals in a research report on Wednesday, January 7th. Barclays started coverage on shares of Amneal Pharmaceuticals in a research note on Monday, December 8th. They issued an “overweight” rating and a $15.00 price objective on the stock. Weiss Ratings reissued a “hold (c)” rating on shares of Amneal Pharmaceuticals in a research report on Wednesday, October 8th. Finally, Piper Sandler restated an “overweight” rating and issued a $13.00 target price (up previously from $11.00) on shares of Amneal Pharmaceuticals in a report on Friday, October 31st. Four analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $13.80.

Amneal Pharmaceuticals Stock Performance

The company’s 50 day simple moving average is $12.46 and its 200 day simple moving average is $10.53. The stock has a market cap of $4.19 billion, a PE ratio of 666.83 and a beta of 1.34.

Amneal Pharmaceuticals (NASDAQ:AMRX) last issued its quarterly earnings results on Thursday, October 30th. The company reported $0.17 EPS for the quarter, beating analysts’ consensus estimates of $0.12 by $0.05. Amneal Pharmaceuticals had a negative return on equity of 185.60% and a net margin of 0.20%.The company had revenue of $784.51 million during the quarter. Amneal Pharmaceuticals has set its FY 2025 guidance at 0.750-0.80 EPS. Equities research analysts expect that Amneal Pharmaceuticals, Inc. will post 0.53 earnings per share for the current year.

Insider Transactions at Amneal Pharmaceuticals

In other Amneal Pharmaceuticals news, EVP Nikita Shah sold 131,856 shares of Amneal Pharmaceuticals stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $11.92, for a total value of $1,571,723.52. Following the sale, the executive vice president owned 146,403 shares of the company’s stock, valued at approximately $1,745,123.76. The trade was a 47.39% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Ted C. Nark sold 50,000 shares of the stock in a transaction that occurred on Monday, November 17th. The shares were sold at an average price of $11.72, for a total transaction of $586,000.00. Following the transaction, the director directly owned 291,029 shares of the company’s stock, valued at $3,410,859.88. This represents a 14.66% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 231,856 shares of company stock worth $2,743,724 over the last three months. 17.45% of the stock is owned by insiders.

Hedge Funds Weigh In On Amneal Pharmaceuticals

Institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. increased its position in Amneal Pharmaceuticals by 2.3% in the third quarter. Vanguard Group Inc. now owns 17,954,973 shares of the company’s stock worth $179,729,000 after buying an additional 403,582 shares during the last quarter. Rubric Capital Management LP grew its stake in shares of Amneal Pharmaceuticals by 5.3% during the 3rd quarter. Rubric Capital Management LP now owns 12,334,941 shares of the company’s stock worth $123,473,000 after acquiring an additional 624,609 shares during the period. Dimensional Fund Advisors LP grew its stake in shares of Amneal Pharmaceuticals by 2.5% during the 3rd quarter. Dimensional Fund Advisors LP now owns 5,431,134 shares of the company’s stock worth $54,361,000 after acquiring an additional 133,764 shares during the period. Nantahala Capital Management LLC increased its holdings in Amneal Pharmaceuticals by 14.7% in the 2nd quarter. Nantahala Capital Management LLC now owns 4,367,438 shares of the company’s stock worth $35,333,000 after acquiring an additional 558,877 shares during the last quarter. Finally, Assenagon Asset Management S.A. raised its stake in Amneal Pharmaceuticals by 75.0% in the 4th quarter. Assenagon Asset Management S.A. now owns 3,761,739 shares of the company’s stock valued at $47,398,000 after acquiring an additional 1,611,698 shares during the period. Hedge funds and other institutional investors own 31.82% of the company’s stock.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.